person · Reporting owner

Opipari Anthony W.

Disclosed activity across 1 company

Tapewire entity: 48235
SEC CIK: 0002131341

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Odyssey Therapeutics, Inc.ODTX · Entity 4850	See Remarks	May 07, 2026	May 12, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Odyssey Therapeutics, Inc.

Report date May 07, 2026 · Filed May 12, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,502	Ending reported balance After 2026-05-11 transaction · row 3 3 source rows · reconciled sequence Row 1 · 2026-05-11 · Conversion · Acquired 6,965 · Balance 6,965 F1: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F3: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. Row 2 · 2026-05-11 · Exercise / conversion · Acquired 541 · Balance 7,506 F5: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. Row 3 · 2026-05-11 · Tax withholding · Disposed 4 · Balance 7,502 F5: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6: Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise.
Series A Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-11 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2026-05-11 · Conversion · Disposed 18,531 · Balance 0 F1: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
Series B Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-11 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2026-05-11 · Conversion · Disposed 11,083 · Balance 0 F2: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
Series C Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-11 transaction · row 6 Instrument identity requires review; Table II rows are not merged. 1 source row Row 6 · 2026-05-11 · Conversion · Disposed 20,000 · Balance 0 F3: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
Series D Convertible Preferred StockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2026-05-11 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2026-05-11 · Conversion · Disposed 17,545 · Balance 0 F4: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06	Direct	250,203	Reported balance After 2026-05-07 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2026-05-07 · Grant · Acquired 250,203 · Balance 250,203 F8: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $18.00 · Expires 2036-05-06	Direct	27,777	Reported balance After 2026-05-07 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2026-05-07 · Grant · Acquired 27,777 · Balance 27,777 F9: Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Common Stock as traded on the Nasdaq Capital Market, subject to the Reporting Person's continued service on such vesting date.
Series D Warrants (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.10	Direct	0	Reported balance After 2026-05-11 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2026-05-11 · Exercise / conversion · Disposed 5,263 · Balance 0 F5: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

F2: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration.

F3: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

F4: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration.

F5: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis.

F6: Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise.

F7: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering.

F8: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date.

F9: Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Common Stock as traded on the Nasdaq Capital Market, subject to the Reporting Person's continued service on such vesting date.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	Exercise / conversionSeries D Warrants (Right to Buy) · Derivative	5,263	Not disclosed Strike: $0.10	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 10 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 541 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F5 · derivative.exercise_date: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F5 · derivative.expiration_date: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	ConversionSeries D Convertible Preferred Stock · Derivative	17,545	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 7 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,806 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4 · price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4 · derivative.exercise_date: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4 · derivative.expiration_date: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	ConversionSeries C Convertible Preferred Stock · Derivative	20,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 6 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,058 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3 · price: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3 · derivative.exercise_date: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F3 · derivative.expiration_date: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	ConversionSeries B Convertible Preferred Stock · Derivative	11,083	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 5 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,194 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2 · price: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2 · derivative.exercise_date: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F2 · derivative.expiration_date: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F7 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	ConversionSeries A Convertible Preferred Stock · Derivative	18,531	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 4 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,907 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · price: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.exercise_date: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F1 · derivative.expiration_date: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F7 · derivative.underlying_shares: Gives effect to the 1-for-9.7170 reverse stock split effected prior to the closing of the Issuer's initial public offering. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	Tax withholdingCommon Stock	4	$18.00	$72.00	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · nonDerivative · entry 3 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,502 F5 · kind: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. F6 · shares: Pursuant to the terms of the warrants, the Issuer withheld 4 warrant shares to pay the exercise price in connection with the net exercise. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	Exercise / conversionCommon Stock	541	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · nonDerivative · entry 2 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,506 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · price: The warrants to purchase shares of common stock were automatically exercised into shares of Common Stock by their terms immediately prior to the closing of the Issuer's initial public offering on a net exercise basis. Read SEC document
May 11, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	ConversionCommon Stock	6,965	Not disclosed	Not disclosed	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · nonDerivative · entry 1 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,965 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The Series A Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F2 · price: The Series B Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.2837 basis for no additional consideration. F3 · price: The Series C Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. F4 · price: The Series D Preferred Stock automatically converted into Common Stock immediately prior to the closing of the Issuer's initial public offering on a 1-for-9.7170 basis for no additional consideration. Read SEC document
May 07, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	GrantStock Option (Right to Buy) · Derivative	27,777	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 9 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,777 Underlying: Common Stock · 27,777 shares Expires 2036-05-06 F9 · derivative.exercise_date: Option vests upon the first occurrence of the total market capitalization of the Issuer being equal to or in excess of $1,500,000,000, based on a 5-day volume-weighted average price of a share of Common Stock as traded on the Nasdaq Capital Market, subject to the Reporting Person's continued service on such vesting date. Read SEC document
May 07, 2026 Filed May 12, 2026 00:30 UTC	Odyssey Therapeutics, Inc. ODTX · Entity 4850	GrantStock Option (Right to Buy) · Derivative	250,203	$0.00 Strike: $18.00	$0.00	Disclosure SEC source: 0001193125-26-217584 · ownership.xml · derivative · entry 8 Opipari Anthony W. · CIK 0002131341 · See Remarks 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,203 Underlying: Common Stock · 250,203 shares Expires 2036-05-06 F8 · derivative.exercise_date: Option vests in forty-eight (48) equal monthly installments, with the first installment scheduled to vest on June 7, 2026, subject to the Reporting Person's continued service on each such vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.